Columbus, OH (March 2023) – InfinixBio, a biotechnology company helping companies advance product development through the regulatory approval process, announces the appointment of Craig McElroy, Ph.D., as the new Vice President of the company’s Pharmacokinetics Division.
Dr. McElroy brings over 20 years of research and leadership experience to his executive role at InfinixBio. As Vice President, McElroy reports directly to Nick Henderson, InfinixBio’s CEO, and will be responsible for the growth, strategic planning, compliance, and coordination of the Pharmacokinetics Division.
“We are extremely pleased to have someone with Craig’s extensive background and experience join InfinixBio as we continue to expand our company’s service offerings,” said Henderson. “His deep domain expertise and broad understanding of the drug development process complements our assay development and virtually all our services. In his previous role at Ohio State University, we witnessed the energy and insight Craig brings to his work, validating our decision to bring him onto our executive team.”
Before accepting the executive role at InfinixBio, Dr. McElroy held various research and professorship posts at Ohio State University and Battelle Memorial Institute. During this time, he received numerous awards for performance and leadership and is cited in many publications.
In a statement following the public announcement of his appointment, McElroy enthused:
“I am honored and excited to join the InfinixBio team of experienced scientists, researchers, and drug development experts whose singular vision is to enable a rapid path to market, fast-tracking the benefits people can receive from our clients’ technology. The InfinixBio Rapid Innovate Model™ represents a unique and common-sense approach to accelerate product development, and I am excited to expand their capabilities to the Pharmacokinetics area.”
About InfinixBio
InfinixBio is a full-service, cost-effective CRO that partners with clients to expand capabilities and meet critical milestones for FDA drug and device regulatory requirements. Its cross-functional interdisciplinary team comprises expert scientists and PhDs operating in multiple BSL Level II labs.
Their Rapid Innovate ModelTM helps companies quickly accelerate technology from early development through preclinical and into the clinical trial phase. InfinixBio currently has over 50 patents, either issued or pending.
To learn more about InfinixBio, please visit www.infinixbio.com.
Media and Partnership Inquiries Contact
Please contact Nick Henderson at nhenderson@infinixbio.com.
Our experienced lab team is here to help. Reach out today to learn more.
Back to Blog
